Why the study?
Does early and prolonged RAS blockade with perindopril or losartan improve blood pressure and renal lesions in male Lyon hypertensive rats after treatment withdrawal?
Does early and prolonged RAS blockade with perindopril or losartan improve blood pressure and renal lesions in male Lyon hypertensive rats after treatment withdrawal?
Early RAS blockade in Lyon hypertensive rats provides durable nephroprotection that persists after treatment withdrawal, independent of long-term blood pressure lowering.
Answers are grounded in this paper and cite their sources.
Animal data show lasting nephroprotection after RAS blockade withdrawal in rats; extends preclinical evidence but leaves open human translation.
The present work aimed to assess, in Lyon hypertensive (LH) rats, whether an early and prolonged inhibition of the renin-angiotensin system (RAS) could result in a blood pressure (BP) lowering and nephroprotection that persist after its withdrawal. Male LH rats received orally from 3 to 12 wk of age either an angiotensin-converting enzyme inhibitor perindopril at the doses of 0.4 and 3 mg x kg(-1) x day(-1) or an AT(1) receptor antagonist losartan at the dose of 10 mg x kg(-1) x day(-1). BP, histological changes in the kidney, and urinary protein excretion were examined during and 10 wk after cessation of the treatments. Both perindopril and losartan decreased BP, prevented renal lesions, and limited urinary protein excretion. After cessation of the treatment, BP returned to the level of never-treated LH rats in rats having received 3 mg x kg(-1) x day(-1) of perindopril while it remained slightly lower in those treated with 0.4 mg x kg(-1) x day(-1) of perindopril or with losartan. This lack of marked persistent antihypertensive effect contrasted with a durable decrease in urinary protein excretion and improvement of the renal histological lesions. In conclusion, it is possible to separate the BP-lowering effects of RAS blockade from those on glomerulosclerosis and urinary protein excretion.
No takes yet. Share an insight, caveat, or question.
Bertram et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: